Drugs / Humanized 3F8 Bispecific Antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03860207 | Feb 2019 → Oct 2021 | neuroblastoma, osteosarcoma | Y-mAbs Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Humanized 3F8 Bispecific Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03860207 ↗ |
| Known as | Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) | “Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb)” NCT03860207 ↗ |
| Route | Intravenous | “Hu3F8-BsAb is given IV over \~1-3 hours” NCT03860207 ↗ |